Revenue from operations rose 35.4% YoY to Rs 3,676 crore from Rs 2,715 crore. Sequentially, revenue increased 19.4% from Rs 3,080 crore.

Profit before tax increased 65.0% YoY to Rs 1,505 crore from Rs 912 crore. Sequentially, PBT rose 27.5% from Rs 1,180 crore.

Total expenditure increased 16.1% YoY to Rs 2,252 crore from Rs 1,940 crore. Cost of raw materials consumed rose 93.4% to Rs 1,812 crore from Rs 937 crore. Employee expenses increased 25.4% to Rs 444 crore from Rs 354 crore. Interest costs rose 62.5% to Rs 13 crore, while depreciation increased 25.7% to Rs 142 crore from Rs 113 crore.

The company reported a foreign exchange gain of Rs 24 crore in Q2 FY27, compared with a gain of Rs 63 crore in the corresponding quarter last year.

Consolidated net cash inflow from operating activities stood at Rs 384 crore during H1 FY27, lower than Rs 1,645 crore in H1 FY26.

Divi's Laboratories is engaged in the manufacture of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients.